Dept. of Nuclear Medicine, University of Aachen, Aachen, Germany BACKGROUND: The follow-up of glioblastoma patients may be difficult with conventional MRI since reactive blood-brain barrier alterations with contrast enhancement can mimick tumor progression ("pseudoprogression¤), especially early after completion of radiochemotherapy. METHODS:
Twenty-six glioblastoma patients with newly appearance or an increase of enhancing lesions (.25%) on standard MRI with gadolinium-based contrast agents within the first 12 weeks after completion of radiochemotherapy with concomitant temozolomide (median time, 7 weeks) were additionally examined by amino acid PET using O-(2-[ F-FET uptake kinetic parameters (i.e., time-to-peak and patterns of the time-activity curves (TAC)) were evaluated. The presence of pseudoprogression / early tumor progression was based on the clinical course (progression-free survival (PFS) . / ≤ 6 mo) and/or histopathological findings. Imaging results were also related to overall survival (OS). RESULTS: Pseudoprogression was confirmed in 14 of 26 patients. TBR max and TBR mean of 18 F-FET / 11 C-MET uptake were significantly higher in patients with early tumor progression (n ¼ 12) than in patients with pseudoprogression (TBR max , 3.6 + 0.8 vs. 2.4 + 0.4; TBR mean , 2.5+ 0.3 vs. 1.8 + 0.2; both P , 0.001). Furthermore, patterns of TAC were significantly different in both groups (P ¼ 0.04) and presence of MGMT promoter methylation was significantly higher in patients with pseudoprogression (P ¼ 0.02). Receiver-operating-characteristic analysis yielded a TBR max of 2.9 as an optimal cut-off to identify early tumor progression (sensitivity, 92%; specificity, 93%; accuracy, 92%; AUC, 0.96 + 0.04; P , 0.001). Univariate survival analyses revealed that a TBR max , 2.9 predicted both a significantly longer PFS (median PFS, 21 vs. 5 months; P , 0.001) and OS (median OS, 33 vs. 12 months; P ¼ 0.007). CONCLUSIONS: Amino acid PET contributes significantly in diagnosing pseudoprogression. Neuro-Oncology 16:v138 -v158, 2014 . doi:10.1093 Published by Oxford University Press on behalf of the Society for Neuro-Oncology 2014. 
